Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/KCT0008268
KCT0008268Not yet recruitingUnknown

An exploratory clinical study of safety and effectiveness of Samul-tang extract on controlling fatigue in women after a miscarriage

Konyang University Hospital0 sites58 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Unknown
Status
Not yet recruiting
Enrollment
58
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20(Year) to 39(Year) (—)
Sex
Female

Inclusion Criteria

  • •1. a history of 2 or more miscarriages with blood natural killer cell level 16.1% or higher or blood natural killer cell cytotoxicity E:T ratio 50:1 34.3% or higher
  • •2. recent miscarriage: 2- 6 months
  • •3. Chalder Fatigue Scale Questionnaire (CFQ) 15 or higher

Exclusion Criteria

  • •(1) Pregnant women (pregnant test positive) or lactating women
  • •(2) Patients with autoimmune diseases (antiphospholipid antibodies, lupus, etc.)
  • •(3) A person with anatomical factors of recurrent miscarriage
  • •(4) Those with uncontrolled endocrine factors (hyperthyroid disease, diabetes, etc.)
  • •(5) Patients with liver and renal dysfunction (ALT or AST, 3 times the normal upper limit when screening, and blood creatine or BUN 2 times the normal upper limit)
  • •(6) A person with a history of severe organic diseases (heart, lung, liver, and kidney disease)
  • •(7) Persons with central nervous system disorders or psychiatric history or taking psychotropic drugs
  • •(8) A person who has taken a drug that may affect the improvement of fatigue, fatigue symptoms within two weeks prior to the screening visit or is scheduled to take it during the study period;
  • •(9) A person who has taken the relevant medication for the purpose of repeated miscarriage treatment within two weeks prior to the screening visit or is scheduled to take it during the period of administration of this study.
  • •(10) A person who has taken or plans to take any health functional food, food, medicine or other herbal medicine (pharmaceutical) that may affect the effectiveness of the test drug within two weeks prior to the screening visit [see list and criteria below]
  • •(11) Those who have a history of serious drug allergies or are hypersensitive to the main ingredients and their components of the test drug: Those who have genetic problems such as galactose intolerance, Lapp lactose (lactose) degradation enzyme deficiency, or glucose-galactose absorption disorder.
  • •(12) A person who has participated in another clinical trial in which treatment intervention has been performed within the last three months;
  • •(13) Any other person deemed inappropriate by the clinical trial director or clinical trial manager to participate in this clinical trial
  • •(14) Those subject to clinical trials that require prompt immunoglobulin treatment or assisted reproductive procedures at the judgment of the clinical trial manager

Investigators

Similar Trials

Recruiting
Unknown
Exploratory study of hochuekkito for exercise capacity of patients with heart failure (HET Study)Heart failure patients scheduled to undergo home-based cardiac rehabilitationheart failure
JPRN-jRCTs031230348Amiya Eisuke30
Completed
Not Applicable
A Clinical Study Evaluating the Safety and Effectiveness of the Ultrasound-guided Modified Thread Carpal Tunnel Release with Smartwire®; Pilot StudyDiseases of the nervous system
KCT0006013The Catholic University of Korea, Incheon St. Mary's Hospital15
Active, not recruiting
Phase 1
A clinical study to evaluate the safety and effectiveness of NOVOCART® 3D plus compared to the standard of care (microfracture) in the treatment of cartilage defects of the knee.Repair of localized, full-thickness cartilage defects of the femoral condyle (medial, lateral or trochlea) of 2-6cm².MedDRA version: 20.0Level: PTClassification code 10052913Term: Cartilage operationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10007705Term: Cartilage damageSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10057104Term: Cartilage repairSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10064112Term: Cartilage graftSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-005798-22-LVTETEC – Tissue Engineering Technologies – AG261
Active, not recruiting
Phase 1
A clinical study to evaluate the safety and effectiveness of NOVOCART® 3D plus compared to the standard of care (microfracture) in the treatment of cartilage defects of the knee.Repair of localized, full-thickness cartilage defects of the femoral condyle (medial, lateral or trochlea) of 2-6cm².MedDRA version: 20.0Level: PTClassification code 10052913Term: Cartilage operationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10007705Term: Cartilage damageSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10057104Term: Cartilage repairSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10064112Term: Cartilage graftSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-005798-22-PLTETEC – Tissue Engineering Technologies – AG261
Active, not recruiting
Phase 1
A clinical study to evaluate the safety and effectiveness of NOVOCART® 3D plus compared to the standard of care (microfracture) in the treatment of cartilage defects of the knee.Repair of localized, full-thickness cartilage defects of the femoral condyle (medial, lateral or trochlea) of 2-6cm².MedDRA version: 20.0Level: PTClassification code 10052913Term: Cartilage operationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10007705Term: Cartilage damageSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10057104Term: Cartilage repairSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10064112Term: Cartilage graftSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-005798-22-LTTETEC – Tissue Engineering Technologies – AG261